Vaccines produced in transgenic plants constitute a promising alternative to conventional immunogens, presenting the possibility of stimulating secretory and systemic immunity against enteric pathogens when administered orally. Protection against enteric pathogens affecting newborn animals requires, in most cases, the stimulation of lactogenic immunity. Here, the group presents the development of an experimental immunogen based on expression of an immunorelevant peptide, eBRV4, of the VP4 protein of bovine rotavirus (BRV), which has been described as harbouring at least one neutralizing epitope as well as being responsible for the adsorption of the virus to epithelial cells. The eBRV4 epitope was efficiently expressed in transgenic alfalfa as a translational fusion protein with the highly stable reporter enzyme b-glucuronidase (bGUS), which served as a carrier, stabilized the synthesized peptide and facilitated screening for the higher expression levels in plants. Correlation of expression of the eBRV4 epitope in plants with those presenting the highest bGUS activities was confirmed by a Western blot assay specific for the BRV peptide. The eBRV4 epitope expressed in plants was effective in inducing an anti-rotavirus antibody response in adult female mice when administered either intraperitoneally or orally and, more importantly, suckling mice born from immunized female mice were protected against oral challenge with virulent rotavirus. These results demonstrate the feasibility of inducing lactogenic immunity against an enteric pathogen using an edible vaccine produced in transgenic plants.
INTRODUCTION
Transgenic plants have been increasingly utilized for the expression of immunogenically relevant antigens since their use was first reported by Mason et al. (1992) , and they currently represent a practical alternative to traditional production strategies involving fermentation procedures and manipulation of active pathogens (Arakawa et al., 1998; Carrillo et al., 1998 Carrillo et al., , 2001 Castañó n et al., 1999; Dus Santos et al., 2002; Gó mez et al., 1998 Gó mez et al., , 2000 Haq et al., 1995; Mason et al., 1992 Mason et al., , 1996 Mason et al., , 1998 McGarvey et al., 1995; Richter et al., 2000; Wigdorovitz et al., 1999) .
In addition to their use as bioreactors for the production of vaccine antigens, plants also provide an adequate system for oral delivery of recombinant immunogens by including them in the diet. A number of viral and bacterial antigens produced in plants have already been shown to be immunogenic when orally administered: among them are Norwalk virus capsid protein (Mason et al., 1996) , Escherichia coli heat-labile enterotoxin (Haq et al., 1995) , cholera toxin B subunit (Arakawa et al., 1998) , gS glycoprotein of transmissible gastroenteritis virus (Gó mez et al., 2000), VP1 of foot-and-mouth disease virus (Wigdorovitz et al., 1999) and the enterotoxigenic E. coli fimbrial and rotavirus enterotoxin (Yu & Langridge, 2001 ). This approach is especially relevant when used for enteric pathogens since oral immunization may be capable of eliciting appropriate immune mechanisms for the induction of protective responses.
Rotaviruses are the principal aetiological agents of severe acute gastroenteritis in numerous mammalian species throughout the world (Kapikian & Chanock, 1996) . Newborn calves are susceptible to rotavirus infection during the first weeks of life, thus making it difficult to actively immunize the animals before exposure to the virulent pathogen. However, colostral antibodies produced in rotavirus-vaccinated mothers have been reported to confer passive protection to the newborn, as shown in an experimental murine model (Offit & Clark, 1985) as well as in the natural host (Fernandez et al., 1996; Kim et al., 2002; Saif et al., 1983) .
Rotavirus particles possess six structural proteins that are organized in an inner core, and a surrounding viral capsid composed of two protein layers. One of the outer capsid proteins, VP4, forms spikes composed of homodimers of the protein that emerge from the virion surface layer (Shaw et al., 1993) . The amino acid sequence involved in the adsorption of bovine rotavirus (BRV) to epithelial cells has been mapped to a VP4 region made up of 24 aa (eBRV4) (Ijaz et al., 1995) , which also included at least one neutralizing epitope. In vivo experiments performed in mice demonstrated that peptides representing the eBRV4 sequence were able to mediate protection by induction of neutralizing antibodies, as well as by competing with the virus in the infection of epithelial cells (Ijaz et al., 1998) .
In this study, we present the development of an experimental edible immunogen based on the use of recombinant eBRV4 peptide expressed in transgenic alfalfa plants. The eBRV4 peptide was expressed fused to the enzyme bglucuronidase (bGUS) in order to reduce the proteolysis of the peptide within plant cells, and also to facilitate the screening of a large number of individuals to select those plants expressing the highest levels of the recombinant antigen (Dus Santos et al., 2002; Gil et al., 2001) . Transgenic alfalfa plants expressing significant levels of the fusion protein eBRV4-bGUS were used to demonstrate the ability of the chimeric protein to induce protective lactogenic immunity against a virulent rotavirus in suckling mice born from immunized adult female mice.
METHODS
Plasmid construction and transformation of Agrobacterium tumefaciens vectors. A 56 bp DNA fragment (eBRV4a) encoding the 232-242 portion of VP4 from BRV strain C486 (Ijaz et al., 1991) was obtained by hybridizing complementary synthetic oligonucleotides. An additional BamHI restriction site and start codon were added at the 59 end and the native XbaI restriction site was preserved at the 39 end. Similarly, a second 64 bp DNA fragment (eBRV4b) encoding the 241-255 sequence of VP4 was produced, including the native XbaI restriction site at the 59 end and an additional XmaI restriction site at the 39 end. In addition, the native VP4 DNA sequences were adapted to the more frequent Arabidopsis thaliana plant codon usage (Chiapello et al., 1998) in both cases. The resulting forward sequences for the eBRV4a and eBRV4b oligonucleotides were 59-ATTCGTCGACGGATCCATGTGTAACATCGCTCCTGCTTCTATC-GTTTCTAGAACTG-39 and 59-AGTCTCTAGAAACATCGTTTACA-CTAGAGCTCAGCCTAACCAGGATATCGCTATCCCGGGACGT-39, respectively. After hybridization, the eBRV4a DNA fragment was digested with BamHI and XbaI and cloned into the pUC19 intermediate plasmid (New England BioLabs) to produce the pUC19-eBRV4a plasmid. The eBRV4b DNA fragment was digested with XbaI and XmaI and inserted into pUC19-eBRV4a, previously digested with the same enzymes, to generate the pUC-eBRV4 vector, which contained the complete sequence of the eBRV4 epitope. The sequence encoding eBRV4 was then removed from pUC-eBRV4 by digestion with BamHI and XmaI and recloned into the pBI121 vector (BD Clontech), in-frame with the bGUS gene located downstream of the XmaI site of the vector and under the control of the cauliflower mosaic virus promoter (CaMV 35S). The resulting plasmid (pBI121-eBRV4-bGUS) encoded the recombinant protein eBRV4-bGUS, containing the BRV eBRV4 epitope fused to the N terminus of the bGUS protein (Fig. 1a) .
The pBI121-eBRV4-bGUS binary vector was introduced into Agrobacterium tumefaciens strain LBA 4404 by electroporation using the procedure described by Shen & Forde (1989) . Petioles and embryos of alfalfa clone C2-3, kindly provided by Dr B. McKersie and Dr S. Bowley (Plant Biotechnology Division, Department of Plant Agriculture, University of Guelph, Canada), were co-cultivated with transformed A. tumefaciens and cultured in vitro as described by Shetty & McKersie (1993) . The in vitro selection was performed using 50 mg kanamycin l 21 as described by McKersie et al. (1993) . After five individual transformation events, 62 different transgenic plants were selected for their ability to grow in the presence of kanamycin.
Detection of the eBRV4-bGUS gene in transgenic plants.
The presence of the recombinant genes in transgenic alfalfa plants was detected by PCR (Carrillo et al., 1998) . Total nucleic acids were extracted from samples of approximately 50 mg of leaves using DNAzol (Gibco) following the manufacturer's specifications. The primers 59-TCGACGGATCCATGTGTAAC-39 (forward) and 59-CG-ATACCCGGGATAGCGATA-39 (reverse) were used to specifically amplify a 96 bp DNA fragment from the eBRV4-bGUS recombinant gene.
Analysis of eBRV4-bGUS expression in transgenic plants
Expression of the eBRV4-bGUS fusion product in transgenic plants was initially studied by measuring bGUS enzymic activity and detecting expression of the eBRV4 epitope by Western blot analysis.
Detection of bGUS activity. Expression of bGUS in plant tissues was quantified by fluorimetry as described by Dus Santos et al. (2002) . Briefly, 100 mg of fresh plant tissue was frozen using liquid nitrogen and ground, and the resulting powder resuspended in GUS extraction buffer (50 mM sodium phosphate pH 7?0, 10 mM b-mercaptoethanol, 10 mM Na 2 EDTA pH 8?0, 0?1 % L-laurylsarcosine, 0?1 % Triton X-100). Samples were clarified at 12 000 g for 10 s and total soluble protein (TPS) was quantified by the Bradford assay (Bio-Rad). Five micrograms of TPS was dissolved in 400 ml of GUS reaction buffer, containing 1 mM 4-methylumbelliferyl b-D-glucuronide, and incubated at 37 uC. The reaction was stopped at different times by the addition of 0?2 M Na 2 CO 3 and read by fluorimetry against a standard concentration curve obtained with different concentrations of 4-methylumbelliferone (MU). The results were expressed as nmol MU produced min 21 (mg TPS)
21 in the leaf extracts of the transgenic plants. The assay was repeated independently, at least twice, with each of the tested plants.
Western blot. Fresh plant tissue (100 mg) was ground as described above and resuspended in 0?1 ml of extraction buffer containing 1 mM PMSF in PBS.
Immunoprecipitation was done according to Al-Yousif et al. (2000) , using sera from mice immunized with semi-purified C486 BRV particles, and protein G-Sepharose 4 Fast Flow (Pharmacia Biotech). Samples were mixed with an equal volume of sample buffer (50 mM Tris/HCl pH 7?5, 1 mM PMSF, 8 M urea, 1 % SDS, 2 mM DTT and 2 % b-mercaptoethanol), boiled for 10 min, separated by a 12?5 % SDS-PAGE and blotted to Immobilon P (Millipore) membranes. Blots were blocked overnight with PBS containing 0?05 % Tween 20 (PBST)/ 3 % skimmed milk (all subsequent steps were performed using this buffer) and incubated with a bovine serum raised against BRV C486. The membrane was then washed with PBST, and incubated with a goat anti-bovine IgG peroxidase-labelled serum (KPL, MD, USA) for 1 h at 37 uC. After washing three times, the reaction was developed by addition of chemiluminescence reagent (NEN).
Animal immunization
BALB/c female mice (60-90 days old) were used for all immunization experiments.
Intraperitoneal vaccination. Mice utilized for serum antibody determinations received six doses, every 3 weeks, with 0?3 ml of an oil vaccine formulated with incomplete Freund's adjuvant containing 150 ml of crude extract obtained from 15 to 20 mg (containing approximately 0?5 mg of the eBRV4 peptide) of fresh leaf tissue from eBRV4-bGUS-expressing plants or non-transformed plants. Those dams used for passive protection experiments received three doses following the same protocol as described above.
Oral immunization. Mice were placed in individual cages and 4 h before treatment were deprived of food and then fed with 0?3 g (containing approximately 6 mg of the eBRV4 peptide) of freshly harvested transgenic or control leaves. This treatment was carried out once a week over a 2 month period.
Analysis of antibody response to plant-expressed eBRVP4 polypeptide
Sera from immunized mice were studied for the presence of BRVspecific antibodies by ELISA and Western blot analysis.
ELISA. A synthetic peptide (p232-254) comprising the amino acid sequence of the eBRVP4 epitope was directly adsorbed onto a microtitre plate at a concentration of 15 mg ml 21 in carbonate/ bicarbonate buffer pH 9?6. Plates were then incubated with PBS/ 0?05 % PBST/3 % normal horse serum (blocking buffer) for 1 h at 37 uC. Blocking buffer was discarded and mouse serum samples were added to the plates, diluted 1 : 20 in the same blocking buffer, and incubated for 1 h at 37 uC. Plates were washed with PBST and were incubated as described above with horseradish peroxidaseconjugated goat anti-mouse IgG (KPL). After extensive washing with PBST, the reaction was developed with o-phenylenediamine (OPD)/H 2 O 2 diluted in citrate buffer pH 5?0. Colour development was stopped by addition of an equal volume of 6 M H 2 SO 4 and absorbance was measured 3 min later at 490 nm in an NR 500 Microplate Reader (Dynatech).
Western blot. Concentrated semi-purified C486 BRV was produced according to Yuan et al. (2001) . BRV antigen was resuspended in SDS-PAGE sample buffer. Electrophoresis and blotting, as well as blocking and washing steps, were performed as already described for detection of the eBRVP4 epitope in the plant tissues. Blots were subsequently incubated for 2 h at 37 uC with mouse serum samples diluted 1/30, washed with PBST and incubated with an alkaline phosphatase-labelled anti-mouse Ig goat antiserum (KPL) for 1 h at Fig. 1. (a) Structure of the T-DNA region used for expression of BRV eBRV4-bGUS fusion protein. The coding sequence for the BRV VP4 peptide (eBRVP4) was inserted into an expression cassette of the pBI121 binary vector and in-frame with the bGUS ORF, from which transcription is driven by CaMV 35S. The T-DNA region also includes the neomycin phosphotransferase (NPT II)-coding region under the nopaline synthetase promoter (NOS-pro). Nopaline synthetase terminator (NOS-ter) elements mediate polyadenylation. (b) Detection of the eBRV4-bGUS gene in transgenic plants by using PCR. Plant DNA was isolated from cell extracts and PCR was performed with a pair of primers that specifically amplify a DNA fragment of 96 bp. Lanes: 1, non-template; 2, DNA from plants transformed with a non-related gene; 3-7, DNA from pBI121-eBRV4-bGUStransformed plants; 8, molecular mass markers; 9, pBI121-eBRV4-bGUS plasmid.
37 uC. After extensive washing the reaction was developed by addition of NBT/BCIP substrate (Bio-Rad).
Challenge experiment. Three weeks before the third immunization, female mice were mated with rotavirus seronegative BALB/c males at a 1 : 1 male-to-female ratio. Challenge experiments with pups born to orally or intraperitoneally immunized dams were performed independently. Newborn mice were left to freely suckle their dams and 5 days after birth were orally challenged with 10 4 fluorescence focus units (f.f.u.) of virulent C486 rotavirus per mouse. This infective virus dose produced diarrhoea in 100 % of control naive animals in mock-treated control groups in our work, similar to that reported by P. A. Offit (Offit & Clark, 1985; Offit et al., 1986) . Infectivity controls of the virulent BRV were repeated for each individual challenge experiment and such results were reproduced consistently. Virus preparations were administered by intubation of the stomach with a soft flexible plastic feeding tube and pups were inspected for diarrhoea for 24 h after challenge by gentle palpation of the abdomen (Ijaz et al., 1987) .
RESULTS

Production of transgenic alfalfa plants containing the eBRV4-bGUS gene
After A. tumefaciens-mediated transformation in vitro of petioles and embryos of alfalfa, transformed plants were initially selected for their ability to grow in agar medium containing kanamycin. Selection was carried out in five consecutive rounds and selected individuals were tested by PCR for the presence of the eBRV4-bGUS fusion gene. The analysis showed the presence of an amplified product of the expected size (96 bp) in all plants transformed with pBI121-eBRV4-bGUS vector (Fig. 1b) . This product was absent from non-transformed plants as well as in kanamycin-resistant plants harbouring an unrelated gene. The presence of the nptII gene included in the vector to confer the kanamycin-resistant phenotype to the transformants was also investigated in the same plant DNA samples. As expected, specific amplification of a 344 bp product was consistently detected only in transformed plants (data not shown).
Analysis of bGUS activity and its correlation with eBRV4 epitope expression in eBRV4-bGUS transgenic alfalfa plants bGUS activity was assessed in 62 transgenic individuals harbouring the eBRV4-bGUS gene. As expected, recombinant plants presented variable levels of bGUS activity (Fig. 2a) , but approximately 4 % of the individuals tested had a significantly high level of expression of the bGUS protein. Some plants presenting significantly high bGUS activity (plants 4, 10, 17 and 46; Fig. 2a ) were analysed by Western blotting for expression of the eBRV4 epitope fused to bGUS protein. As shown in Fig. 2(b) , expression of the BRV epitope was effectively associated with bGUS activity in the tested lines. Transgenic eBRV4 peptide reacted against a specific anti-VP4 antiserum in Western blot analysis giving a unique distinctive band of approximately 67 kDa, the molecular mass expected for the eBRV4-bGUS fusion protein (Fig. 2b) . The approximate concentration of the recombinant eBRV4-bGUS expressed in transgenic lines 17 and 46 was estimated at between 0?4 and 0?9 mg (g TPS) 21 using a methodology based on the bGUS enzymic activity obtained with a known control, p135-160-bGUS (Dus Santos et al., 2002) , and that obtained with eBRVP4 (data not shown).
Induction of a rotavirus-specific immune response in mice immunized with plant extracts expressing eBRV4-bGUS Immunogenicity of the plant-expressed eBRV4 epitope was assessed in mice by intraperitoneal or oral immunization with fresh leaves or extracts of transgenic plants. Intraperitoneal immunization of female mice was carried out as described in Methods using a pool of extracts from the eBRV4-bGUS-expressing plants 17 and 46. Fifteen days later, immunized animals were bled and serum samples from animals immunized with eBRV4-bGUS plant antigen were assessed for the presence of BRV-specific antibodies. Nitrocellulose membranes blotted with BRV particles resolved by SDS-PAGE were used for Western blot analysis and results are shown in Fig. 3(a) . Although the pooled sera from mice immunized with plant extracts expressing a non-related antigen did not show a significant reaction (Fig. 3a, lane 2) , two serum pools from mice immunized with the plant-produced eBRV4-bGUS (Fig. 3a, lanes 3  and 4) reacted against a protein that had a similar electrophoretic mobility to the protein recognized by both anti-VP4 monoclonal antibody IA8 and a serum pool from BRV-immunized mice (Fig. 3a, lanes 1 and 5, respectively) . These results were confirmed by ELISA using eBRV4 peptide as the detection antigen, in that all mice vaccinated with the alfalfa-derived eBRV4-bGUS showed a significantly higher absorbance reading than did the mice immunized with control antigen (Fig. 3b) .
Importantly, animals fed with fresh leaves from plants expressing eBRV4-bGUS also developed a significant antirotavirus humoral response that was not present in controlvaccinated mice (Fig. 3d, e) .
Also of interest was the observation that the BRV antibody response elicited in a second group of dams, immunized by either the intraperitoneal or oral routes, was also passively transferred to their offspring. Pups born from intraperitoneally or orally immunized dams showed levels of anti-BRV specific antibodies that were consistently positive, and comparable to those of their respective mothers (Fig. 3c and e, respectively).
Virus challenge of pups born to dams immunized with plant-produced eBRV4-bGUS fusion protein
Since dams transferred significant passive antibody to their offspring, we determined whether the pups would be protected against rotavirus challenge. Pups were orally inoculated using 10 4 f.f.u. of BRV isolate C486 and then observed over a 24 h period for the presence of diarrhoea. Challenge experiments demonstrated that, regardless of the route of immunization administered to the dams, all groups showed a significant degree of protection when compared with animals immunized with extracts from plants transformed with a non-related gene, as determined by Fisher's exact test (Table 1) .
DISCUSSION
Since the concept of using transgenic plants for vaccine production was first presented by Mason et al. (1992) , several authors have described the expression of vaccine antigens using this methodology (Arakawa et al., 1998; Carrillo et al., 1998 Carrillo et al., , 2001 Castañó n et al., 1999; Dus Santos et al., 2002; Gil et al., 2001; Gó mez et al., 1998 Gó mez et al., , 2000 Haq et al., 1995; Mason et al., 1996 Mason et al., , 1998 McGarvey et al., 1995; Wigdorovitz et al., 1999) .
The demonstration that some of these antigens were immunogenic when orally administered (Arakawa et al., 1998; Gó mez et al., 2000; Haq et al., 1995; Mason et al., 1996; Gil et al., 2001; Wigdorovitz et al., 1999) encouraged the study of other proteins and peptides expressed in plants in order to develop edible vaccines, especially for those pathogens which invade the host organism via the oral route. In addition, in diseases affecting newborn animals, passive protection conferred by colostrum and milk is the main protective mechanism against these infections. In the present work, we describe the production of transgenic alfalfa plants expressing the eBRV4 epitope from structural protein VP4 of rotavirus fused to bGUS protein, and their use in conferring passive protection in an experimental host.
Fusion of the eBRV4 peptide to the reporter protein allowed us to easily detect the highest-expressing plant lines by measuring their bGUS enzymic activity, as with previous reports that showed a positive correlation between bGUS activity and accumulation of the fused vaccine peptides (Dus Santos et al., 2002; Gil et al., 2001) .
Our results showed that plant-derived eBRV4-bGUS was able to induce a rotavirus-specific antibody response in mice when administered either intraperitoneally or orally. In addition, oral immunization was achieved not only by feeding the animals with fresh transgenic alfalfa leaves, but also by intragastric immunization with crude extracts from transgenic plants (data not shown).
Most notable was the observation that immunization of female mice induced not only an anti-BRV humoral response, but also elicited a specific secretory antibody response in those mice that they were able to transfer to their offspring through colostrum. Consequently, suckling mice presented specific rotavirus antibodies in their serum at levels comparable to those in their respective dams. Depending on the route of immunization of the dams, 71 or 76 % of the experimentally challenged pups were protected from virus infection. In contrast, for those animals born to mothers immunized with control plant antigens, protection was 15 or 21 % when compared with unvaccinated controls.
The VP4-derived eBRV4 epitope has been shown to provide protection from virulent BRV either by binding to the target cell in vitro (Ruggeri & Greenberg, 1991) or in vivo (Ijaz et al., 1998) , or by inducing antibodies that are able to prevent virus binding to the gut epithelial cells (Ijaz et al., 1991) . Passive protection to BRV challenge using this peptide has also been previously reported in mice (Ijaz et al., 1991) , and in cattle by immunization with a BRV VP8* protein fragment subunit antigen (Lee et al., 1995) . The same antigen has also been expressed in plants via a plant virus-based vector and it was also able to induce passive protection in a murine model by intraperitoneal immunization of the dams (D. M. Perez-Filgueira and others, unpublished).
We believe that our results demonstrate the feasibility of this strategy, since we could provide reasonable protection to susceptible pups through a mucosal immune response induced by an orally administered vaccine formulation obtained from transgenic plants. The results presented here also support the concept of using transgenic plants as a novel and safe system for vaccine production, which could become a very attractive alternative in animal health. The fact that feeding animals with transgenic plants expressing a recombinant antigen caused a systemic immune response demonstrates the prospect of using recombinant plants as both an expression and delivery system for oral vaccines, even against antigens for which a systemic immune response is required. The establishment of food plant-based oral immunization methods for microbial antigens may represent an inexpensive alternative to conventional fermentation systems for vaccine production, as food plants can be grown inexpensively in large quantities and provide a practical and feasible delivery system. 
